PACS Group: Strong Comeback That's Backed By Improving Fundamentals

PACS Group (PACS) is reaffirmed as a 'Buy' for long-term investors, following a 257% rebound from oversold lows. PACS demonstrates robust credit health with $795M liquidity, 0.1x net leverage, and strong interest coverage, supporting aggressive organic and acquisition-driven growth. Guidance for FY26 includes 8% revenue growth and 22% adjusted EBITDA growth, with margin expansion driven by facility maturation and industry consolidation opportunities.